Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G17DT Immunogen plus Gemcitabine in Pancreatic Cancer
NCT00044031Phase 3Completed
- Sponsor
- Cancer Advances, Inc.
- Start
- Feb 2001
- Primary completion
- Apr 2004
01
Overview
Phase 3, randomised, double-blind trial of G17DT immunogen in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cancer Advances, Inc. Primary endpoint: Overall Survival at 12 months. Started Feb 2001; status: completed.
02
Drugs
G17DT immunogen
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00044031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044031.